LICENSE AND COLLABORATIVE ARRANGEMENTS (Details) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended			3 Months Ended		6 Months Ended	68 Months Ended	1 Months Ended	3 Months Ended		11 Months Ended	47 Months Ended	1 Months Ended	36 Months Ended	1 Months Ended	3 Months Ended		6 Months Ended		1 Months Ended		3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014 Mallinckrodt Inc	Apr. 30, 2014 Mallinckrodt Inc	Nov. 30, 2008 Mallinckrodt Inc item	Jun. 30, 2014 Mallinckrodt Inc	Mar. 31, 2014 Mallinckrodt Inc	Jun. 30, 2014 Mallinckrodt Inc	Jun. 30, 2014 Mallinckrodt Inc item	Aug. 31, 2012 Janssen Pharmaceuticals, Inc.	Dec. 31, 2013 Janssen Pharmaceuticals, Inc.	Mar. 31, 2013 Janssen Pharmaceuticals, Inc.	Dec. 31, 2013 Janssen Pharmaceuticals, Inc. item	Jun. 30, 2014 Janssen Pharmaceuticals, Inc.	Mar. 31, 2014 Ironwood Pharmaceuticals, Inc.	Jun. 30, 2014 Ironwood Pharmaceuticals, Inc. item	Aug. 31, 2011 Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) Commercialization Agreement	Jun. 30, 2014 Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) Commercialization Agreement	Jun. 30, 2013 Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) Commercialization Agreement	Jun. 30, 2014 Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) Commercialization Agreement	Jun. 30, 2013 Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) Commercialization Agreement	Jul. 31, 2008 Salix Pharmaceuticals, Inc. (formerly Santarus Inc.) Promotion Agreement	Jul. 31, 2005 Valeant Pharmaceuticals International, Inc.	Jun. 30, 2014 Valeant Pharmaceuticals International, Inc.	Jun. 30, 2013 Valeant Pharmaceuticals International, Inc.	Jun. 30, 2014 Valeant Pharmaceuticals International, Inc.	Jun. 30, 2013 Valeant Pharmaceuticals International, Inc.
License and collaborative arrangements
Number of products to be developed by utilizing Acuform technology							4
Number of products elected to develop							2
Upfront fees and milestones payment received											$ 27,500,000					$ 10,000,000
Upfront fee received											4,000,000	10,000,000						3,400,000						12,000,000	25,000,000
Upfront fee received for formulation work to be performed under the agreement											1,500,000
Number of milestone payments received											4							3
Clinical development milestone payments											500,000
Milestone payments following FDA's Acceptance										10,000,000	5,000,000
Milestone payment received					5,000,000	10,000,000
Number of projects completed															2
License and other revenue	5,760,000	760,000	17,520,000	3,724,000									1,400,000	2,200,000						400,000	400,000	700,000	700,000			400,000	400,000	800,000	800,000
Milestone revenue recognized								5,000,000	10,000,000								1,000,000
Royalties on net product sales, percentage in 2011																			26.50%
Royalties on net product sales, percentage in 2012																			29.50%
Royalties on net product sales, percentage in 2013 and 2014																			32.00%
Royalties on net product sales, percentage in 2015 and beyond																			34.50%
Royalty revenue	430,000	15,097,000	925,000	29,178,000																	14,200,000		27,500,000
Upfront agreement fee deferred revenue balance																				$ 2,300,000		$ 2,300,000				$ 11,700,000		$ 11,700,000